Chinese Academy of Medical Sciences COVID-19 vaccine

Dr. LIANG Xiao of SRRSH Invited as ELSA 2023 Sole Keynote Speaker from Mainland China

Retrieved on: 
Wednesday, October 11, 2023

Dr. LIANG Xiao delivered a speech titled "New Era of Minimally Invasive Surgery for Hepatocellular Carcinoma in China", sharing the latest and significant technological advancements in minimally invasive surgery with the audience.

Key Points: 
  • Dr. LIANG Xiao delivered a speech titled "New Era of Minimally Invasive Surgery for Hepatocellular Carcinoma in China", sharing the latest and significant technological advancements in minimally invasive surgery with the audience.
  • With great enthusiasm, Dr. LIANG introduced SRRSH, which is dedicated to promoting and applying minimally invasive surgical techniques.
  • The Hospital is one of the leading institutions in China with the broadest range of minimally invasive surgical procedures and involvement in various disciplines.
  • With Dr. CAI Xiujun, the President of SRRSH, leading the way, the Hospital has progressed steadily, achieving remarkable results.

China Review Studio and Chinese Red Cross Foundation Release "Generation Vax" Documentary for Broadcast Internationally

Retrieved on: 
Monday, October 2, 2023

BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese Red Cross Foundation recently released a documentary on YouTube named Generation Vax. Directed by internationally renowned director Mitchell Farkas, the film focuses on the theme of China's Covid-19 vaccine by deeply diving into the safety, effectiveness, and publicity of China's vaccines.

Key Points: 
  • BEIJING, Oct. 2, 2023 /PRNewswire/ -- China Review Studio, in collaboration with Chinese Red Cross Foundation recently released a documentary on YouTube named Generation Vax.
  • Directed by internationally renowned director Mitchell Farkas, the film focuses on the theme of China's Covid-19 vaccine by deeply diving into the safety, effectiveness, and publicity of China's vaccines.
  • The film also reveals the story of how clinical phase III of China's vaccine has been conducted in Brazil.
  • The second half of the film documents China's calls for the world to work together to face down public safety incidents together.

BioCity Signs Collaboration Agreement with AstraZeneca on BC3402, a monoclonal antibody targeting anti-TIM-3, in Combination with IMFINZI (durvalumab) for the Treatment of Advanced Hepatocellular Carcinoma in China

Retrieved on: 
Thursday, September 28, 2023

BioCity will lead the trial, which has received IND approval by the National Medical Products Administration (NMPA).

Key Points: 
  • BioCity will lead the trial, which has received IND approval by the National Medical Products Administration (NMPA).
  • Moreover, BC3402 has shown synergistic anti-cancer activity with mAbs targeting PD-1 and CTLA-4, which are important clinical targets for liver cancer.
  • The collaboration between BioCity and AstraZeneca will evaluate the potential for the combination of BC3402 with durvalumab to improve the clinical outcome of subjects with HCC.
  • Both companies may be expected to explore further collaboration opportunities to boost innovation in China in HCC and possibly other types of cancer.

SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

Retrieved on: 
Monday, September 11, 2023

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.

Key Points: 
  • Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
  • SINOVAC’s SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023.
  • The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China.
  • China’s National Medical Products Administration has approved SINOVAC’s SA55 Nasal Spray for clinical trial in the prevention of COVID-19 infections, in April 2023.

Medical Aesthetics Returning to the True of Medicine - The 5th Anniversary Celebration of SHANGHAI MOYOM BIOTECH (APHRANEL)

Retrieved on: 
Friday, August 25, 2023

Invited representatives of the medical aesthetics industry held a wonderful discussion and joint oath from the perspective of "Practitioners of returning medical aesthetics to the true of medicine".

Key Points: 
  • Invited representatives of the medical aesthetics industry held a wonderful discussion and joint oath from the perspective of "Practitioners of returning medical aesthetics to the true of medicine".
  • Different from other anniversary celebrations, Shanghai MOYOM's 5th anniversary celebration on August 18, 2023 was more like a collision of ideas and a call of value return in the medical aesthetics industry.
  • Shanghai MOYOM's 5th Anniversary Celebration, it is a big gathering of people in the medical aesthetics industry and a big collision of ideas.
  • Shanghai MOYOM Bio is not only an enterprise, but also the practitioner and guardian of the clean environment of the medical aesthetics industry.

Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment

Retrieved on: 
Thursday, July 6, 2023

This study is led by Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences.

Key Points: 
  • This study is led by Peking Union Medical College Hospital and the Chinese Academy of Medical Sciences.
  • "Completing patient enrollment for the Phase III bridging clinical trial of Hexvix® marks a significant milestone for Asieris Pharmaceuticals."
  • said Dr. Linda Wu, Chief Development Officer of Asieris," We are thrilled to have reached this stage in the development of a drug that has the potential to revolutionize the diagnosis of bladder cancer.
  • Our goal is to provide healthcare professionals with a more effective and reliable way for patient with bladder cancer."

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

Retrieved on: 
Thursday, July 6, 2023

OSLO, Norway, July 6, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial.

Key Points: 
  • OSLO, Norway, July 6, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial.
  • The objective of the multicenter Phase III trial is to support regulatory approval of Hexvix in Mainland China.
  • The clinical trial follows the same protocols for registration studies in countries where Hexvix already has market authorization.
  • The phase III clinical trial obtained approval from the NMPA in the first quarter of 2022 and Hexvix was subsequently included in the real-world clinical data pilot program.

Photocure Partner Asieris announces completion of enrollment for Hexvix Phase III clinical trial in China

Retrieved on: 
Thursday, July 6, 2023

OSLO, Norway, July 6, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial.

Key Points: 
  • OSLO, Norway, July 6, 2023 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has communicated today that it has completed patient enrollment for the Hexvix® Phase III bridging trial.
  • The objective of the multicenter Phase III trial is to support regulatory approval of Hexvix in Mainland China.
  • The clinical trial follows the same protocols for registration studies in countries where Hexvix already has market authorization.
  • The phase III clinical trial obtained approval from the NMPA in the first quarter of 2022 and Hexvix was subsequently included in the real-world clinical data pilot program.

TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody

Retrieved on: 
Friday, June 16, 2023

HEFEI, China, June 16, 2023 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody.

Key Points: 
  • HEFEI, China, June 16, 2023 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody.
  • "We are thrilled to receive FDA clearance for the clinical trial of TGI-6," said Professor Zhigang Tian, founder of TGI and member of the Chinese Academy of Engineering and the Academia Europaea.
  • With this significant milestone, TGI is actively seeking global partners to collaborate on the development, clinical trials, and eventual commercialization of TGI-6.
  • With FDA clearance for the clinical trial of TGI-6, the company is poised to advance the development of precise therapies for solid tumors.

TG ImmunoPharma Announces FDA Clearance for Clinical Trial of TGI-6 Bispecific Antibody

Retrieved on: 
Friday, June 16, 2023

HEFEI, China, June 16, 2023 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody.

Key Points: 
  • HEFEI, China, June 16, 2023 /PRNewswire/ -- TG ImmunoPharma Co., Ltd. (TGI), a leading biotech company focused on the development of novel immuno-oncology therapies, is pleased to announce that the FDA has granted clearance for the clinical trial of TGI-6, its groundbreaking bispecific antibody.
  • "We are thrilled to receive FDA clearance for the clinical trial of TGI-6," said Professor Zhigang Tian, founder of TGI and member of the Chinese Academy of Engineering and the Academia Europaea.
  • With this significant milestone, TGI is actively seeking global partners to collaborate on the development, clinical trials, and eventual commercialization of TGI-6.
  • With FDA clearance for the clinical trial of TGI-6, the company is poised to advance the development of precise therapies for solid tumors.